98 related articles for article (PubMed ID: 31119463)
21. Development of nociceptin receptor (NOP) agonists and antagonists.
Mustazza C; Bastanzio G
Med Res Rev; 2011 Jul; 31(4):605-48. PubMed ID: 20099319
[TBL] [Abstract][Full Text] [Related]
22. N/OFQ-NOP System in Food Intake.
Micioni Di Bonaventura MV; Micioni Di Bonaventura E; Cifani C; Polidori C
Handb Exp Pharmacol; 2019; 254():279-295. PubMed ID: 31073870
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Assays for Investigating the NOP Receptor.
Malfacini D; Caló G
Handb Exp Pharmacol; 2019; 254():69-89. PubMed ID: 30725284
[TBL] [Abstract][Full Text] [Related]
24. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
Daga PR; Polgar WE; Zaveri NT
J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
[TBL] [Abstract][Full Text] [Related]
25. The Nociceptin/Orphanin FQ System and the Regulation of Memory.
Moulédous L
Handb Exp Pharmacol; 2019; 254():259-278. PubMed ID: 30430261
[TBL] [Abstract][Full Text] [Related]
26. NOP receptor pharmacological profile - A dynamic mass redistribution study.
Malfacini D; Simon K; Trapella C; Guerrini R; Zaveri NT; Kostenis E; Calo' G
PLoS One; 2018; 13(8):e0203021. PubMed ID: 30161182
[TBL] [Abstract][Full Text] [Related]
27. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.
Zaveri N; Jiang F; Olsen C; Polgar W; Toll L
AAPS J; 2005 Oct; 7(2):E345-52. PubMed ID: 16353914
[TBL] [Abstract][Full Text] [Related]
28. Nociceptin/Orphanin FQ and Urinary Bladder.
Angelico P; Barchielli M; Lazzeri M; Guerrini R; Caló G
Handb Exp Pharmacol; 2019; 254():347-365. PubMed ID: 30430260
[TBL] [Abstract][Full Text] [Related]
29. The History of N/OFQ and the NOP Receptor.
Reinscheid RK; Civelli O
Handb Exp Pharmacol; 2019; 254():3-16. PubMed ID: 30689090
[TBL] [Abstract][Full Text] [Related]
30. NOP Receptor Ligands and Parkinson's Disease.
Mercatelli D; Pisanò CA; Novello S; Morari M
Handb Exp Pharmacol; 2019; 254():213-232. PubMed ID: 30689087
[TBL] [Abstract][Full Text] [Related]
31. [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain.
Berthele A; Platzer S; Dworzak D; Schadrack J; Mahal B; Büttner A; Assmus HP; Wurster K; Zieglgänsberger W; Conrad B; Tölle TR
Neuroscience; 2003; 121(3):629-40. PubMed ID: 14568023
[TBL] [Abstract][Full Text] [Related]
32. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.
Toll L; Cippitelli A; Ozawa A
CNS Drugs; 2021 Jun; 35(6):591-607. PubMed ID: 34057709
[TBL] [Abstract][Full Text] [Related]
33. In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.
Ferrari F; Malfacini D; Journigan BV; Bird MF; Trapella C; Guerrini R; Lambert DG; Calo' G; Zaveri NT
Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805972
[TBL] [Abstract][Full Text] [Related]
34. NOP-Related Mechanisms in Substance Use Disorders.
Ciccocioppo R; Borruto AM; Domi A; Teshima K; Cannella N; Weiss F
Handb Exp Pharmacol; 2019; 254():187-212. PubMed ID: 30968214
[TBL] [Abstract][Full Text] [Related]
35. The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders.
Toll L
Curr Pharm Des; 2013; 19(42):7451-60. PubMed ID: 23448477
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
[TBL] [Abstract][Full Text] [Related]
37. Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats.
Economidou D; Fedeli A; Fardon RM; Weiss F; Massi M; Ciccocioppo R
Peptides; 2006 Dec; 27(12):3299-306. PubMed ID: 17097763
[TBL] [Abstract][Full Text] [Related]
38. [Nphe1,Arg14,Lys15]N/OFQ-NH2 is a competitive antagonist of NOP receptors in the periaqueductal gray.
Chiou LC; Liao YY; Guerrini R; Calo' G
Eur J Pharmacol; 2005 May; 515(1-3):47-53. PubMed ID: 15896734
[TBL] [Abstract][Full Text] [Related]
39. The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus.
D'Oliveira da Silva F; Azevedo Neto J; Sturaro C; Guarino A; Robert C; Gavioli EC; Calo G; Mouledous L; Ruzza C
Neuropharmacology; 2022 Jul; 212():109077. PubMed ID: 35513173
[TBL] [Abstract][Full Text] [Related]
40. The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.
Jong L; Zaveri N; Toll L
Bioorg Med Chem Lett; 2004 Jan; 14(1):181-5. PubMed ID: 14684324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
